Regional Disparities Threaten Effectiveness Of U.K. Cancer Drugs Fund
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry association warns of Cancer Drugs Fund's potential to worsen regional variations in access to cancer treatments.
You may also be interested in...
Cancer Drugs Fund Extended As Pharma Calls For U.K. HTA Rethink
Drug manufacturers say the announced two-year extension for Britain’s Cancer Drugs Fund would not have been needed if NICE was not so focused on cost.
Despite Discount, High Price Again Fells Novartis’ Afinitor At NICE
Novartis’ discount for Afinitor in breast cancer has failed to convince NICE that the drug is cost-effective.
European HTA Highlights: Discounts Soften NICE Approach But Germany’s IQWiG Shows Its Teeth
It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.